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The members of MAGE gene family are highly expressed in human hepatocellular carcinoma (HCC). In the present study, we
tested the tumour-speciﬁc MAGE-1 and MAGE-3 transcripts in the peripheral blood of HCC patients by nested RT–PCR to
detect the circulating tumour cells and evaluate their potential clinical implication. Of 30 HCC patients, the positive rate of
MAGE-1 and MAGE-3 transcripts was 43.3% (13 out of 30) and 33.3% (10 out of 30) in PBMC samples, whilst the positive
rate was 70% (21 out of 30) and 53.3% (16 out of 30) in the resected HCC tissue samples, respectively. The positivity for at
least one MAGE gene transcript was 63.3% (19 out of 30) in PBMC samples of HCC patients and 83.3% (25 out of 30) in the
resected HCC tissue samples. MAGE-1 and/or MAGE-3 mRNA were not detected in the PBMC of those patients from
whom the resected HCC tissues were MAGE-1 or MAGE-3 mRNA negative, nor in the 25 PBMC samples from healthy
donors. The detection of MAGE transcripts in PBMC was correlated with the advanced stages and tumour size of the HCC,
being 82.4% (14 out of 17) in tumour stages III and IVa, 56.6% (ﬁve out of nine) in stage II, and null (nought out of four) in
stage I. The serum a-FP in 33.3% (10 out of 30) of HCC patients was normal or slightly elevated (540 ng ml
71). However,
six of these 10 patients (a-FP 540 ng ml
71) were MAGE-1 and /or MAGE-3 mRNA positive in their PBMC. The follow-up
survey of MAGE mRNA in PBMC was performed in 12 patients. Seven patients with persistent MAGE-1 and/or MAGE-3
mRNA positive or from negative turned to positive died because of metastasis and/or recurrence. In striking contrast, all four
patients with MAGE-1 and/or MAGE-3 mRNA from positive turned to negative and one patient with persistent MAGE-3
transcript negative are alive after last test. Collectively, detection of MAGE transcripts with follow-up survey in PBMC is a
feasible and reliable assay for the early prediction of the relapse and prognosis of the HCC patients.
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Hepatocellular carcinoma (HCC) ranks among the most common
malignancies in China, Japan, Southeast Asia, South Africa and
some South European areas. Though regular sonographic examina-
tion and serum alpha-fetoprotein (a-FP) can detect small HCC at
an early stage and there are many modalities of treatment, the
recurrence and metastasis are frequent and the prognosis remains
unsatisfactory. The high recurrence rate is probably attributed to
the dissemination of HCC cells into blood circulation. Early detec-
tion of metastatic tumour cells is critical to identify HCC patients
at high risk of relapse and for the prescriptive therapy. However, it
is difﬁcult to detect such dissemination of HCC cells through
blood route with conventional techniques.
The reverse transcription-polymerase chain reaction (RT–PCR)
has made it possible to detect molecular markers present at low
copy numbers for the evaluation of micro-metastasis. In 1991,
Smith and colleagues (Smith et al, 1991) ﬁrst successfully adopted
RT–PCR technique to assess tyrosinase messenger RNA (mRNA)
as a tumour marker to detect circulating melanoma cells. Then,
the gene transcripts of both tissue-speciﬁc and tumour speciﬁc
markers have been applied in RT–PCR based diagnosis of micro-
metastasis of tumour cells in peripheral blood, such as the
tyrosinase and MAGE-3 transcripts in melanoma (Brossart et al,
1993; Foss et al, 1995; Hoon et al, 1995; Smith et al, 1991), prostate
speciﬁc antigen (PSA) and prostate speciﬁc membrane antigen
(PSMA) encoding gene transcripts in prostate cancer (Israeli et
al, 1994, 1995), carcinoembryonic antigen (CEA) in colon cancer
(Mori et al, 1996), CD44 and CK-19 transcripts in breast cancer
(Dall et al, 1995; Kruger et al, 1996) and tyrosinase hydroxylase
in neuroectodermal tumour (Miyajima et al, 1996; Naito et al,
1991). With respect to HCC, both albumin and a-FP mRNA are
widely used as tumour markers for HCC cells in circulation (Chou
et al, 1994; Hillaire et al, 1994; Jiang et al, 1997; Kar and Carr,
1995; Komeda et al, 1995; Lemoine et al, 1997; Malek et al,
1999; Matsumura et al, 1994; Wong et al, 1997). However, the
reliability using them as tumour markers have been challenged,
because both albumin and a-FP are abundantly expressed in
normal liver cells, they are released to the peripheral blood by
either surgical injury of the liver for the disease other than HCC
or by hepatitis virus infection (Chou et al, 1994; Jiang et al,
1997; Lemoine et al, 1997; Malek et al, 1999; Wong et al, 1997).
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www.bjcancer.comIt is, therefore, necessary to screen tumour-speciﬁc markers, which
are speciﬁcally and frequently expressed in HCC.
Since 1991, MAGE-1 (melanoma associated antigen) gene has
been cloned from melanoma cells (van der Bruggen et al, 1991), there
are up-to-date 17 MAGE genes being cloned (De Plaen et al, 1994;
Lucas et al, 1998; Lurquin et al, 1997; Muscatelli et al, 1995; van
der Bruggen et al, 1991). The MAGE genes are activated in sperma-
tozoa but silent in normal somatic cells. In cancers, these genes are
re-activated and their encoding proteins are frequently expressed in
various histological types of cancers. Because of this distribution
characteristic, the MAGE proteins are termed as cancer-testes (CT)
antigens (De Plaen et al, 1994). Both others and our group have
reported that MAGE-1 and MAGE-3 transcripts were highly
expressed in HCC tissues, but not in non-HCC liver tissues, nor in
non-HCC liver diseases such as HBV/HCV infection and cirrhosis
(Cai et al, 1999, 2000; Chen et al, 1999; Tahara et al, 1999; Yamashita
et al, 1996). Therefore, we investigated if the MAGE gene transcripts
could be used as tumour marker to speciﬁcally detect metastasis of
HCC cells in peripheral blood. We have developed a nested RT–
PCR assay to detect MAGE-1 and MAGE-3 transcripts in PBMC,
through which to evaluate them as the early markers to unveil hema-
togeneous dissemination of HCC cells and their potential clinical
implications.
MATERIALS AND METHODS
Cell lines and human tissues
Mel-Ed1, ME235, 2.2ETI (three melanoma cell lines were kindly
provided by Dr Qi-Yuan Chen from Ludwig Institute for Cancer
Research, Melbourne Tumour Biology Branch, Melbourne, Austra-
lia) grown in Dulbecco’s modiﬁed eagle medium with 10% foetal
calf serum were served as positive controls for the expression of
MAGE-1 and MAGE-3 gene transcripts. Samples of HCC tissues
and adjacent non-cancerous tissues were collected from HCC
patients (n=30) who underwent hepatectomy at either the 2nd or
8th Hospitals of Peking University Health Science Center. All
samples were frozen in liquid nitrogen until RNA extraction.
Informed consent was obtained from each patient before the study
was conducted. The Ethic Committee of the University approved
the study protocol. The stage of HCC was determined according
to the criteria outlined by the Liver Cancer Study Group of Japan
(1989). The clinical diagnosis was conﬁrmed by pathological exam-
ination.
Blood samples
Whole blood samples were drawn on the day before surgery from
these 30 HCC patients. Control blood samples were collected from
25 healthy donors. Approximately 20 ml of blood from each patient
were collected in two tubes, 10 ml in heparinized tube for the separa-
tion of peripheral blood mononuclear cells (PBMC), and another
10 ml in plain tubes for the separation of serum to detect serum a-
FP. For PBMC separation, 10 ml blood was diluted with 10 ml
RPMI1640 medium containing 10% foetal bovine serum and placed
on a Ficoil-Hypaque layer (GIBCO BRL, USA), and the PBMC were
collected after density gradient centrifugation.
RT–PCR
Total RNA was extracted from frozen tissue specimens (50–100 mg)
and freshly isolated PBMC using TRIZOL (GIBCO BRL) reagent
according to the protocol provided by the manufacturer. Total
RNA (2.5 mg) was primed with an Oligo(dT)15 oligonucleotide
(Promega) and reverse-transcribed with Superscript II (GIBCO
BRL) according to manufacturer’s instructions. The ampliﬁcation
reaction (50 ml) contained 1 ml cDNA, 2.5 ml each of 10 mM primers
and 2.5 U Taq polymerase (GIBCO BRL) in buffer solution. The PCR
ampliﬁcations were performed by pre-programmed Thermal Cycler
(Perkin-Elmer, USA) under the following conditions: (1) cDNA from
liver tissues: The samples were denatured at 948C for 4 min followed
by the ampliﬁcation of MAGE-1 (948C for 45 s, 658C for 45 s, and
728C for 45 s) and MAGE-3 (948C for 45 s and 728C for 3 min)
for 35 cycles. The sequence of MAGE-1 and MAGE-3 primers and
length of PCR products were as follows: MAGE-1: forward-5'-CGG
CCG AAG GAA CCT GAC CCA G-3' (CHO-14) and reverse-5'-
GCT GGA ACC CTC ACT GGG TTG CC-3' (CHO-12), size, 421
base pair (bp); MAGE-3: forward-5'-TGG AGG ACC AGA GGC
CCC C-3' (AB-1197) and reverse-5'-GGA CGA TTA TCA GGA
GGC CTG C-3' (BLE-5), size, 725 bp. (2) cDNA from PBMCs: The
reaction conditions for the ﬁrst round of PCR were completely the
same as those for PCR ampliﬁcation of cDNA in liver tissues, but
were carried out just for 25 cycles. For the second round of PCR,
5 ml of a 1: 10 dilution of the ﬁrst-round PCR product was used in
combination with 2.5 ml each of 10 mM MAGE-1 (M1nestX:
forward-5'-ACA GAG GAG CAC CAA GGA GAA G-3'; M1nestY:
reverse-5'-AGT TGA TGG TAG TGG GAA AGG C-3', size, 299 bp)
or MAGE-3 (M3nestX: forward-5'-CGG AGG AGC ACT GAA
GGA GAA G-3'; M3nestY: reverse-5'-CCT CCT CTT CTT GGT
TGC TGG-3' size, 371 bp) inner primers, which were designed with
Gene Runner analysis software 3.04 (Hastings Software Inc.). After
initial heating at 948C for 2 min, 35 cycles of PCR were then carried
out for the ampliﬁcation of MAGE-1 (948C for 45 s, 658C for 45 s,
and 728C for 45 s) and MAGE-3 (948C for 45 s, 698C for 45 s, and
728C for 45 s). (3) To assess the integrity of the cDNA, b-actin
(CHO15: forward-5'-GGC ATC GTG ATG GAC TCC G-3' and
CHO16: reverse-5'-GCT GGA AGG TGG ACA GCG A-3', size,
613 bp) was ampliﬁed for 28 cycles (45 s at 948C, 558C and 728C
separately). For analysis, 6 ml of reaction product was run in 2% agar-
ose gel (Promega, USA), followed by ethidium bromide staining and
digital camera photographing.
Cloning and sequencing of MAGE cDNA
Puriﬁed MAGE-1 and MAGE-3 cDNA from PCR ampliﬁcation was
cloned into pGEM-T Easy Vector (Promega) by T4 DNA ligase and
ampliﬁed in E. coli, JM105. The positive colonies were selected
using EcoRI digestion of mini-prepared DNA. The putative MAGE
cDNA samples were sequenced with T7 sequencing primers in
Saibaisheng Co., Beijing, China.
Follow-up
Follow-up was obtained from all the patients every 3–6 months
after operation. All the patients were checked with ultrasonogra-
phy, computed tomography (CT) and serum a-FP to conﬁrm if
there were any metastasis and/or recurrence. If possible, whole
blood samples were drawn to get PBMC, then MAGE-1 and
MAGE-3 were ampliﬁed to ﬁnd out any changes in expression of
the two MAGE genes in PBMC, according to the methods as
described above. The endpoint of follow-up was set at the death
of the patient.
Statistical analysis
The statistical analysis was performed by the Fisher’s exact prob-
ability test because the samples were small in number. The level
of signiﬁcance was set at P50.05.
RESULTS
Patients
A total of 30 HCC patients were enrolled in the study. All the
patients had chronic HBV infection with various degrees of cirrho-
sis. Two of the patients were complicated with HCV infection. In
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(1), 110–116all the normal controls, there was no sign of hepatitis or liver func-
tional abnormality. Pathological examination indicated that 16.7%
(5 out of 30) of HCC samples were well differentiated, 46.7% (14
out of 30) moderately and 36.7% (11 out of 30) were poorly differ-
entiated, respectively. Twenty-four (80%) patients had large sized
tumours (54 cm), while the tumour diameter of the other six
patients (20%) was less than 4 cm. According to the TNM classi-
ﬁcation of the tumour, there were 13.3% (4 out of 30) at stage
I, 30% (9 out of 30) at stage II, 30% (9 out of 30) at stage III,
and 26.7% (8 out of 30) at stage IVa, respectively (Table 1).
Sensitivity of the nested RT–PCR technique
To determine the sensitivity of the method, 100-fold serial dilu-
tion experiments were performed using cDNA from 10
7 Mel-
Ed1 cells that express both MAGE-1 and MAGE-3 transcripts.
The cDNA dilutions of 1/10 (10
6 cells), 1/10
3 (10
4 cells), 1/10
5
(10
2 cells), 1/10
7 (one cell) were utilized as templates for two
rounds of RT–PCR ampliﬁcation of MAGE-1 and MAGE-3
transcripts. After the ﬁrst round (25 cycles) of PCR ampliﬁca-
tion, only at the dose of cDNA from 10
6 cells were both
MAGE gene transcripts detected. However, after the second
round (35 cycles) of PCR ampliﬁcation, the two MAGE genes
could be sensitively and clearly detected from the cDNA
contained in about one Mel-Ed1 cell (Figure 1).
Nested RT–PCR results
With two-round RT–PCR ampliﬁcation, the positive rate in blood
samples was 43.3% (13 out of 30) for MAGE-1 transcript and
33.3% (10 out of 30) for MAGE-3 transcript. 63.3% (19 out of
30) of the PBMC samples were positive for at least one type of
the two MAGE gene transcripts (Table 1). Among 25 cases of
MAGE-1 and/or MAGE-3 mRNA positive HCC tissue samples, at
least one of the two MAGE transcripts was detected in the PBMC
of 19 cases of patients. The correlation positive rate was 76% (19
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Table 1 List of MAGE-1 and 3 detection results and common clinical indicators of 30 HCC patients
Case Viral AFP Histol Diameter TNM
Liver tissues PBMC
No Sex Age infection (ng mg
71) diff
a of tumour (cm) stage MAGE-1 MAGE-3 MAGE-1 MAGE-3
1 M 67 B 3.5 Moderate 7 III ++++
2 M 30 B 400 Poorly 7 IVa ++++
3 M 58 B 108 Well 13 IVa ++++
4 M 58 B 400 Moderate 6 III + + + 7
5 F 66 B 400 Moderate 3 II + + 77
6 M 62 B 400 Poorly 2 I + + 77
7 M 46 B 400 Poorly 2 I + + 77
8 F 68 B 146 Well 4 11 + + 77
9 M 42 B 400 Poorly 10 IVa + 7 + 7
10 M 40 B 400 Poorly 4 II + 7 + 7
11 M 61 B 400 Moderate 5 III + 7 + 7
12 M 37 B 400 Well 10 III + 7 + 7
13 M 54 B 380 Moderate 5 II + 777
14 M 57 B 400 Moderate 7 III 7 + 7 +
15 M 68 B 38 Poorly 6 III 7 + 7 +
16 F 71 B 5 Poorly 4 II 7 + 7 +
17 M 47 B 26 Moderate 6 II 7 + 77
18 F 61 B 224 Moderate 2 I 7777
19 F 37 B 20 Moderate 5 III 7777
20 F 60 B 20 Moderate 6 II 7777
21 M 44 B 115 Moderate 10 II + 7 + 7
22 M 40 B 19 Poorly 5 IVa ++++
23 M 61 B 46 Moderate 10 III + + 7 +
24 F 70 B 1210 Poorly 7 IVa + 7 + 7
25 M 62 B 1210 Moderate 6 IVa + + 7 +
26 M 72 B 0.6 Poorly 8 IVa + 7 + 7
27 F 59 B 1.7 Poorly 8 IVa 7777
28 M 45 BC 1210 Moderate 5 III 7777
29 M 72 BC 1210 Well 2.5 II + + + 7
30 F 62 B 5 Well 1.5 I + 777
aHistol diff=histological differentiation.
First round
of PCR
Second round
of PCR
725bp
371bp
421bp
299bp
11 0 2 104 106 BM B1 0 6 104 102 1
MAGE-1 MAGE-3
Figure 1 cDNA derived from 1610
7 Mel-Ed1 cells was 100-fold se-
quentially diluted. After 25 cycles of the ﬁrst round RT–PCR ampliﬁcation,
MAGE-1 and MAGE-3 transcripts were detectable only in the cDNA of
10
6 cells and shown in bands of 421 and 725 bp individually. After the sec-
ond round of 35 cycles of ampliﬁcation, MAGE-1 (299 bp) and MAGE-3
(371 bp) transcripts were detected in the PCR products ampliﬁed from
the cDNA converted from one cell contained mRNA.
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MAGE-3 transcript was not detected in the PBMC of the patients
whose resected HCC tissue samples were negative for MAGE-1 or
MAGE-3 mRNA. In control samples, MAGE-1 or MAGE-3 mRNA
could not be detected in PBMC from 25 healthy donors. The
MAGE-1 and MAGE-3 positive PCR products ampliﬁed from
mRNA of the PBMC samples were cloned into competent bacteria
and three clones from each were randomly picked up and
sequenced. The nucleotide sequence of MAGE-1 or MAGE-3 cDNA
fragments were identical to the database of the GenBank. It
conﬁrms that the RT–PCR products were truly MAGE-1 and
MAGE-3 cDNA (data not shown). The typical electrophoresis of
nested RT–PCR products ampliﬁed from cDNA of PBMC samples
of some HCC patients is shown in Figure 2.
RT–PCR status and clinical indicators
The frequency of MAGE-1 or MAGE-3 transcript positive cases
detected in PBMC of patients with HCC at different stages was:
null (0 out of 4) at stage I, though 3 out of 4 of resected HCC
tissue samples were positive for at least one of the two MAGE tran-
scripts, 56.6% (5 out of 9) at stage II, 77.8% (7 out of 9) at stage
III, and 87.5% (7 out of 8) at IVa. Taken the expression of MAGE
transcripts in HCC tissues into account, the correlation rate of
MAGE-1 or -3 transcript expressed in HCC tissue samples and
detected in PBMC samples was 62.5% (5 out of 8) at stage II,
100% (7 out of 7) at stage III, and 100% (7 out of 7) at IVa.
Of note, MAGE-1 or MAGE-3 mRNA was detected in PBMC in
38.5% (5 out of 13) patients with the HCC at early stages (stages
I and II). MAGE-1 or -3 transcript could be detected in virtually all
PBMC samples of the 14 patients with HCC at stage III or IVa
from whom the resected HCC tissue samples were all positive for
these genes. Three of the 17 patients bearing HCC of stage III or
IVa were MAGE-1 or -3 mRNA negative in both resected HCC
tissues and PBMC. Regarding the size of the cancer, 75% (18
out of 24) and 16.6% (1 out of 6) of blood samples were
MAGE-1 or -3 mRNA positive in the patients with large sized
tumours (54 cm) and small sized tumours (54 cm), respectively.
Clearly, the frequency of the MAGE transcripts detected in PBMC
is in strong correlation with clinical severity. The frequency of the
MAGE transcripts detected in PBMC was signiﬁcantly higher in
HCC patients at stages III and IVa than at stages I and II
(P=0.018) and in large tumours than in small tumours
(P=0.009). The expression of MAGE-1 or -3 transcripts did not
correlate with any of the other parameters, such as the degree of
tumour differentiation, serum a-FP, etc (as listed in Table 1).
a-FP level did not correlate with MAGE transcripts in
blood samples of HCC patients
The cases of a-FP level (40 ng ml
–1) in the serum of patients with
HCC were 3 out of 4 in stage I, 6 out of 9 in stage II, 6 out of 9 in
stage III, and 5 out of 8 in stage IVa. There is no correlation
between the a-FP level and the stages of the cancer. The overall
positive rate of a-FP in serum was 66.7% (20 out of 30) and of
MAGE-1 and/or MAGE-3 mRNA in PBMC samples was 63.3%.
There was no correlation between the positivity of a-FP and MAGE
transcripts in blood samples in each individual HCC patient.
However, 33.3% (10 out of 30) of HCC patients had serum a-FP
lower than 40 ng ml
71. In these 10 patients, six patients had
MAGE-1 or MAGE-3 transcript detected in PBMC samples. It is
noted that among the resected HCC tissue samples from these
10 patients, the MAGE-1 or -3 mRNA was positive in 6 samples,
while negative in another four samples, hence the positive rate of
MAGE-1 or -3 mRNA in PBMC samples among a-FP negative
patients is underestimated. By contrast, in ﬁve patients both
resected HCC tissue and PBMC samples were MAGE-1 or -3
mRNA negative, three patients had the a-FP higher than
40 ng ml
71. Although there is no correlation between the positive
rates of a-FP and MAGE-1 or -3 transcript in blood samples with
respect to each individual patient, combination of the parameters
of a-FP in serum and MAGE-1 or -3 mRNA in PBMC, a higher
positive rate has been achieved (28 out of 30, 93.3%).
Detectable MAGE transcripts in PBMC and prognosis
All the patients with tumour resection were followed-up for the
average time of 13.7 months. Among 19 patients with MAGE-1
and/or MAGE-3 transcripts detected in PBMC, 15 patients died,
one died from liver functional failure, the other 14 patients
(77.8%) died from recurrence and/or metastasis. The death rate
in the patients with undetectable MAGE-1 or MAGE-3 transcript
in PBMC was 2 out of 6 (33.3%). Because of the small number
of patients under investigation, there was no statistical difference
(P40.05) in the death rate or relapse between the two groups of
patients distinguished by preoperative single detection of MAGE-
1 and MAGE-3 mRNA in PBMC. The perturbation of MAGE-1
and/or -3 transcripts in blood after resection of MAGE-1 and/or
-3 positive tumours has been followed up in 12 patients (Table
2). The MAGE-1 or -3 transcript in PBMC was persistently detect-
able in ﬁve patients and all these ﬁve patients died for recurrence
and/or metastasis. In two patients (one at stage II, the another at
stage I), the MAGE transcripts in PBMC were turned from negative
to positive in the following up period, these two patients died of
recurrence and/or metastasis. In contrast, among these 12 patients,
four patients (three in stage II, one in stage III) showed both clin-
ical stable and MAGE-1 or -3 transcript undetectable in PBMC
(i.e., MAGE transcripts from detectable before surgery turned to
negative after surgery). All these four patients are alive 14-months,
12-months, 11-months and 15-months after tumour resection,
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b -actin
MAGE-1
MAGE-3
613 bp
299 bp
371 bp
MPB121 0 1 4 1 6 4 1 96 3
Patient No.
Figure 2 Electrophoresis of second round of PCR products ampliﬁed
from cDNA of PBMC samples of HCC patients. (1) M: molecular marker,
100 bp DNA ladder (Gibco); (2) P: Mel-Ed1, Positive control of nested
MAGE-1 (299 bp) and MAGE-3 (371 bp) transcripts; (3) B: Blank control,
PCR ampliﬁcation in the absence of template; (4) b-actin (613 bp), cDNA
quality control, which was ampliﬁed for one round of 35 cycles and all the
samples shown here were positive; (5) Patient No. 1, 2, 3, 4, 10 showed
MAGE-1 transcript positive, while patient No. 1, 2, 3, 14, 16 showed
MAGE-3 transcript positive: (6) The second band of MAGE-3 transcript
shown in Patient No. 1 and 14 was the genomic DNA with the size of
452 bp.
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with persistent negative of MAGE transcripts in PBMC is alive with
clinical remission 33 months after tumour resection. Thus, the
recurrence and death rate were signiﬁcantly higher in the patients
with persistent detectable, or from undetectable to detectable,
MAGE-1 and MAGE-3 mRNA in PBMC than those patients with
MAGE transcripts from detectable turned to undetectable, or
persistently undetectable, in PBMC (P50.01).
DISCUSSION
Metastasis spreading through vessels is the most important factor
affecting the prognosis of HCC patients. If the HCC cell metastasis
via hematogenous route can be sensitively and speciﬁcally deter-
mined at early stage, more beneﬁcial therapeutic methods could
be manipulated. With the advance of molecular biology, the tech-
nique of RT–PCR ampliﬁcation of speciﬁc DNA sequences using
synthesized oligonucleotide primers that ﬂank the target DNA frag-
ment of interest is increasingly applied in the detection of
micrometastasis of cancer cells (Brossart et al, 1993; Dall et al,
1995; Foss et al, 1995; Hoon et al, 1995; Israeli et al, 1994, 1995;
Kruger et al, 1996; Miyajima et al, 1996; Mori et al, 1996; Naito
et al, 1991; Smith et al, 1991). Our results veriﬁed exponential
ampliﬁcation of target cDNA converted from mRNA allowed to
detect a single malignant cell within millions of normal blood cells
and hence, to sensitively detect the metastatic tumour cells in
peripheral blood (Negrin and Blume, 1991). Apparently, RT–
PCR-based detection of circulating tumour cells is much more
sensitive than that diagnosed by antibody-based serology. In this
study, we have developed a sensitive and speciﬁc technique capable
of detecting one single circulating HCC cell in blood samples using
MAGE-1 and MAGE-3 transcripts as tumour-speciﬁc markers.
Though elevation of serum a-FP has been routinely applied as a
parameter for HCC diagnosis, a-FP transcripts were detected in
normal liver cells, the liver cirrhosis and the liver infectious
diseases such as HBV/HCV infection (Jiang et al, 1997). Further-
more, a-FP transcripts was detected even in the blood samples
from patients without HCC after the surgical injury of the liver,
which results in the shedding of liver cells into circulation under
surgical operation (Lemoine et al, 1997; Malek et al, 1999). Thus,
a-FP represents a liver cell-speciﬁc marker, not a tumour-speciﬁc
marker. In HCC, the majority cases of HCC cells produce a-FP
leading to its elevation in blood samples and providing an adjunct
diagnosis. However, a signiﬁcant proportion of patients does not
have elevated a-FP. We found in this study that 33.3% (10 out
of 30) HCC patients with the serum a-FP lower than 40 ng ml
71.
Our study also showed that the elevation of a-FP is not correlated
with the progression of the HCC. Thus, a-FP is valuable to help
diagnosis of HCC, but not a speciﬁc marker to detect circulating
HCC cells.
MAGE gene transcripts have been regarded as tumour-speciﬁc
markers and found to be highly expressed in a variety histological
types of cancers. In the case of HCC, the positive rate was 46–80%
of MAGE-1 transcript and 42–68% of MAGE-3 transcript in HCC
tissue samples (Cai et al, 1999, 2000; Chen et al, 1999; Tahara et al,
1999; Yamashita et al, 1996). A proportion of 74–86% of the HCC
tissue samples was positive for at least one MAGE gene transcript,
while no expression of MAGE transcripts detected in the surround-
ing non-cancerous tissues, nor in the livers of cirrhosis, HBV/HCV
infection or normal ones (Cai et al, 1999, 2000; Chen et al, 1999;
Tahara et al, 1999; Yamashita et al, 1996). We have reported
previously that MAGE-1 and MAGE-3 transcripts were expressed
in 71 and 78% of resected HCC tissue samples, respectively (Cai
et al, 1999; 2000). In our present study, 83.3% (25 out of 30) of
the HCC tissues were positive for either MAGE-1 or MAGE-3 tran-
script. In conjunction with the prevalent invasion of HCC cells to
hepatic vessels, it is logical to consider that MAGE-1 and MAGE-3
could be the appropriate tumour-speciﬁc markers for the detection
of circulating HCC cells.
With nested RT–PCR assay, 43.3% (13 out of 30), 33.3% (10
out of 30) and 63.3% (19 out of 30) were found to be positive
for MAGE-1, MAGE-3, and MAGE-1 and/or MAGE-3 transcripts,
respectively, in the peripheral blood samples. Detection of MAGE-1
and/or MAGE-3 transcripts in PBMC is closely correlated to the
pathological stages of HCC. The more advanced stages of HCC,
the higher rate of micro-metastasis of cancer cells detectable in
peripheral blood (to compare the positive rate between the HCC
samples in stages III and IVa with those in stages I and II,
P50.02). Concerning the three HCC tissue samples in stage III
or IVa did not express MAGE-1 or MAGE-3 transcript, virtually
all the patients with HCC in stages III and IVa have had cancer
cells metastasized to the peripheral blood. According to the TNM
criteria, the HCC in stage II (T2NoMo) should have no other
metastasis of tumour cells except the possibly intrahepatic metasta-
sis. Assay by nested RT–PCR to detect MAGE-1 and/or MAGE-3
transcripts, the tumour-speciﬁc markers, revealed that 56.6% (5
out of 9) patients with HCC in stage II have already had micro-
metastasis to the peripheral blood, a parameter to detect occult
hematogenous dissemination of HCC cells much earlier than any
other means described. This parameter ﬁrmly indicates that blood
dissemination of tumour cells has already occurred in the early
stage of HCC. It is probably the reason why some patients still
suffered recurrence after radical resection of the tumour. In terms
of actual presence of circulating HCC cells in blood, the TNM
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Table 2 Follow-up survey of MAGE transcripts in PBMC and prognosis of HCC patients
PBMC
Case TNM a a-F -FP P
HCC tissues Before Follow-up
Survival time
No. Age stage (ng ml
71) MAGE-1 MAGE-3 MAGE-1 MAGE-3 MAGE-1 MAGE-3 Pro
a (months)
13 54 II 380 + 777+ 7 R, D
b 6
22 40 IVa 19 + + + + + + R, D 4
23 61 III 46 + + 7 + 7 +R , D 2
24 70 IVa 1210 + 7 + 7 + 7 R, D 6
25 62 IVa 1210 + + 7 + 7 +R , D 3
26 72 IVa 0.6 + 7 + 7 + 7 R, D 1
7 46 I 400 + + 77+ 7 R, D 5
10 40 II 400 + 7 + 777 A
c 15
15 68 III 38 7 + 7 + 77 A1 4
21 44 II 115 + 7 + 777 A1 2
29 72 II 1210 + + + 777 A1 1
5 66 II 400 + + 7777 A3 3
aPro = progression;
bR, D = recurrence and died;
cA = alive.
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and needs to be modiﬁed according to the new technology
approaches.
The important implication for the detection of occult hematogen-
ous metastasis of HCC cells by nested RT–PCR of MAGE-1 and/or
MAGE-3 transcripts is its value in the prediction of recurrence after
treatment and prognosis of the disease. In the follow-up survey in 12
patients after tumour resection, ﬁve patients with persistent expres-
sion of MAGE-1 and/or MAGE-3 transcripts in PBMC samples and
two patients with MAGE-1 and/or MAGE-3 transcripts from negative
tumour resection turned to positive after resection died due to
relapse. In contrast, four patients with MAGE-1 and/or MAGE-3
transcripts in PBMC samples from positive before tumour resection
turned to negative after surgical treatment and one patient with
persistent negative before and after operation are all alive. The differ-
ence between two groups of patients with respect to the recurrence
and death rate has statistic signiﬁcance (P50.01). Apparently, the
continuous positive or negative of circulating tumour cells assessed
by MAGE transcripts in blood cells is closely correlated to the prog-
nosis. Such follow-up survey is not only a predictor for prognosis of
the patients, but also a valuable parameter to judge the effectiveness
of the treatment regime employed. Forthe limited number of patients
in our follow-up survey, our correlation date between the status of
detectable MAGE transcripts in blood and the prognosis of the
patients is preliminary. Quantitative estimation of the number of
circulating HCC cells and the probability of the metastasis in second-
ary sites or reseeding into the liver to cause recurrence needs to be
more detailed analyses in more patients and in long-term follow-up
surveys.
Just in the period of performing follow-up survey required by
referees of the journal, a paper has been published by Miyamoto
et al. (2000). They have used conventional RT–PCR with one-
round ampliﬁcation of MAGE-1 and MAGE-3 transcripts in the
blood samples of HCC patients. In no patients could the MAGE
transcripts be detected in peripheral blood samples prior to surgical
operation. Only after operation could the MAGE transcripts be
detected in peripheral blood with very low positivity (1 out of
11 for each MAGE transcripts). They did not do follow-up survey
with the MAGE transcript detection and prognosis. However, they
detected more MAGE transcripts in the hepatic venous blood and
in the portal venous blood prior, during and after operation with
overall positive rate of 18.3% (13 out of 71 blood specimens
collected from 11 patients), supporting the HCC invasion of the
blood vessels localized in the liver organ. Notably, in their 13 blood
specimens with positive MAGE transcript, only two specimens were
positive for a-FP transcript, consistent with our results.
In summary, detection of a-FP and MAGE transcripts in blood
samples has different signiﬁcance. a-FP is an adjunct assay which
may help early diagnosis of HCC, as a-FP is elevated in some
patients with HCC in stage I, whereas detection of MAGE tran-
scripts in blood, especially with follow up survey, may help to
predict the prognosis and monitoring of the response to the ther-
apy. Combination of both may be more valuable in the diagnosis.
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